Redburn Atlantic upgraded Autolus Therapeutics (AUTL) to Buy from Neutral with an unchanged price target of $13. One week earlier than expected, Autolus announced obe-cel has been approved and is the first cell-therapy to be approved without a risk monitoring program, the analyst tells investors in a research note. The firm is “enthusiastic” about the product and the company’s commercialization abilities and the future potential of obe-cel in autoimmune conditions, supported by its above-consensus sales forecasts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AUTL:
- Autolus Therapeutics Q3 2024 Financial Update and FDA Approval
- Autolus Therapeutics Wins FDA Approval for AUCATZYL®
- Autolus Therapeutics Gains FDA Approval for AUCATZYL®
- Autolus Therapeutics reports Q3 EPS (31c), consensus (21c)
- Autolus estimates cash to drive full launch, commercialization of obe-cel
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
